Accessibility Menu
Allurion Technologies logo

Allurion Technologies(NYSE) ALUR

This security has been delisted. This page is retained for historical reference.

Allurion Technologies last closing stock price
MetricPriceDate
Last closeUSD 4.302026-08-07
Allurion Technologies stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 4.302026-07-31
1 month-19.13%USD 5.322026-07-08
3 month-63.24%USD 11.702026-05-08
Year to date-76.69%USD 18.452025-12-31
1 year-89.61%USD 41.402025-08-07
3 year-99.81%USD 2,250.002023-08-08
5 year-99.83%USD 2,566.082021-08-06
Since inception-99.83%USD 2,589.842021-03-29

ALUR News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

ALUR Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

N/A

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Payout Ratio

N/A

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$6.64M

Operating Income

-$26.61M

EBITDA

-$39.46M

Operating Cash Flow

-$22.70M

Capital Expenditure

$0.00

Free Cash Flow

-$22.70M

Cash & ST Invst.

$5.06M

Total Debt

$29.45M

Allurion Technologies Performance Analysis

Allurion Technologies annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 64,211,000N/A
20232023-12-31USD 53,467,000-16.7%
20242024-12-31USD 32,110,000-39.9%
20252025-12-31USD 15,230,000-52.6%
Allurion Technologies sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-39.4%
Q32025-09-30-21.3%
Q42025-12-3135.9%
Q12026-03-31-18.4%
Allurion Technologies annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -566.31N/A
20232023-12-31USD -890.7057.3%
20242024-12-31USD -48.05-94.6%
20252025-12-31USD -57.1719.0%
Allurion Technologies sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-312.9%
Q32025-09-30-19.5%
Q42025-12-3168.0%
Q12026-03-316.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$2.95M

-47.2%

Gross Profit

$1.23M

-70.5%

Gross Margin

41.70%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

134

N/A

Net Income

-$6.10M

-306.1%

EBITDA

-$4.08M

-153.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$5.06M

-75.2%

Total Debt

$29.45M

-64.5%

Accounts Receivable

$3.48M

-58.2%

Inventory

$2.06M

-38.5%

Long Term Debt

$910.00K

-98.9%

Short Term Debt

$28.55M

+3343.9%

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

-$3.22M

+66.0%

Operating Cash Flow

-$3.22M

+66.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ACONAclarion, Inc.
$2.29-2.55%
AHCOAdaptHealth Corp.
$5.69-5.87%
AMIXAutonomix Medical, Inc.
$10.04-17.50%
BDRXBiodexa Pharmaceuticals Plc
$1.54+4.76%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$133.11+0.16%
TTDThe Trade Desk
$13.80-0.22%
NVDANvidia
$223.96+0.02%
TLTiShares Trust - iShares 20+ Year Treasury Bond ETF
$82.76+0.00%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.